Shares of Myovant Sciences Ltd (NYSE:MYOV) have earned a consensus rating of “Buy” from the eight research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $29.20.

Several research firms recently weighed in on MYOV. JPMorgan Chase & Co. began coverage on Myovant Sciences in a research report on Thursday, September 13th. They set an “overweight” rating and a $39.00 price target on the stock. Zacks Investment Research lowered Myovant Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, July 17th. Finally, ValuEngine raised Myovant Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd.

Shares of NYSE MYOV traded down $0.32 during mid-day trading on Thursday, hitting $26.00. 1,124 shares of the company traded hands, compared to its average volume of 48,794. Myovant Sciences has a 1 year low of $11.30 and a 1 year high of $27.45. The company has a market cap of $1.82 billion, a price-to-earnings ratio of -10.95 and a beta of -1.96. The company has a quick ratio of 3.07, a current ratio of 3.07 and a debt-to-equity ratio of 0.73.

Myovant Sciences (NYSE:MYOV) last announced its earnings results on Tuesday, August 7th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.08). sell-side analysts expect that Myovant Sciences will post -3.91 EPS for the current fiscal year.

In other news, Director Mark Altmeyer bought 3,500 shares of the company’s stock in a transaction on Saturday, November 17th. The shares were bought at an average cost of $13.38 per share, with a total value of $46,830.00. Following the transaction, the director now directly owns 3,500 shares in the company, valued at approximately $46,830. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 3.10% of the company’s stock.

A number of hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC bought a new stake in shares of Myovant Sciences during the 2nd quarter worth about $297,000. Matisse Capital bought a new stake in shares of Myovant Sciences during the 2nd quarter worth about $349,000. Swiss National Bank boosted its stake in shares of Myovant Sciences by 12.7% during the 1st quarter. Swiss National Bank now owns 28,300 shares of the company’s stock worth $602,000 after acquiring an additional 3,200 shares in the last quarter. Platinum Investment Management Ltd. bought a new stake in shares of Myovant Sciences during the 1st quarter worth about $1,152,000. Finally, Millennium Management LLC boosted its stake in shares of Myovant Sciences by 54.3% during the 1st quarter. Millennium Management LLC now owns 106,868 shares of the company’s stock worth $2,273,000 after acquiring an additional 37,602 shares in the last quarter. 21.03% of the stock is currently owned by institutional investors.

Myovant Sciences Company Profile

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Further Reading: How to Invest in the Dividend Aristocrat Index

Analyst Recommendations for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.